Legend Biotech shares jump nearly 61% in U.S. market debut
Shares of Legend Biotech , a cell therapy unit owned by Hong Kong-listed Genscript Biotech , jumped nearly 61% in their stock market debut, signaling strong investor appetite for new listings.